An observational study in Hypertension, sponsored by Scandinavia Pharma. Status unknown at 1 site in Colombia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-23.
Sponsored by Scandinavia Pharma · Observational
Epidemiological study (cross-sectional study) in order to determine the patients who present an adequate control of the Blood Pressure (BP), in a population of Colombian patients diagnosed with Arterial Hypertension (AH) and who are under pharmacological treatment.
OBJECTIVE: To determine the proportion of patients who present an adequate control of the Blood Pressure (BP), in a population of Colombian patients diagnosed with Arterial Hypertension (AH) and who are under pharmacological treatment.
MATERIALS AND METHODS: Epidemiological study (cross-sectional study), multicentre type, in patients older than 18 years with prior diagnosis of AH in Colombia. The blood pressure control will be evaluated as the main variable (only one single blood pressure check in the doctor's office). Other secondary variables to evaluate are: demographical analysis, type (s) of antihypertensive treatment (s) used in patients, level of BP control, adverse events associated with antihypertensive treatment, comorbidities and risk factors, adherence, perception about the possible benefits of the use of combined therapy in "mono-tablet" versus "multi-tablet". The analysis will be carried out from two perspectives: A first descriptive approach and a second analytical approach, with a level of significance of 5%.
6,690 studies on the registry are indexed under Hypertension; 966 are open to participants now.
This study's planned enrollment of 1,100 is above the median of 210 across 1,359 observational studies indexed under Hypertension.
Browse Hypertension studies →Scandinavia Pharma is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Colombian patients
Exclusion Criteria:
Patients with adequate control of the Blood Pressure (BP)
Proportion of patients who present an adequate control of the Blood Pressure (BP)
Time frame: It will be evaluated in each patient (only once, at the time of the interview) throughout the study which is estimated to last 3 years.
Demographic analysis
Characterization of patients
Time frame: It will be evaluated in each patient (only once, at the time of the interview) throughout the study which is estimated to last 3 years.
Treatment analysis
Characterization of treatment (s) used
Time frame: It will be evaluated in each patient (only once, at the time of the interview) throughout the study which is estimated to last 3 years.
Personal history of diseases
Evaluation of personal history of diseases
Time frame: It will be evaluated in each patient (only once, at the time of the interview) throughout the study which is estimated to last 3 years.
Adverse Events related with the treatment
Adverse events associated with the treatment (s)
Time frame: It will be evaluated in each patient (only once, at the time of the interview) throughout the study which is estimated to last 3 years.
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.